T1	Participants 57 117	myometrium and uterine myomas of gnRH analogue-treated women
T2	Participants 494 560	women with uterine myomas, untreated or treated with GnRH analogue
T3	Participants 1212 1231	females with myomas
T4	Participants 569 592	randomly selected cases
T5	Participants 300 358	uterine myomas and in the surrounding unaltered myometrium
